Previous 10 | Next 10 |
– Recipients include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79,...
2023-09-05 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11, 2023 at 8:40 a.m. E.T. The fireside ...
Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test PR Newswire Quest and Sarepta Therapeutics Expand Collaboration to Develop AAV Companion Diagnostics (CDx) for Sarepta's Gene Therapies SECAUCUS, N.J. and CAMBRIDGE, ...
2023-08-24 07:58:18 ET More on Cassava Sciences Cassava Sciences: CMS Data Promising But Many Red Flags Remain; Hold Cassava Sciences: Quest For Alzheimer's Treatment A Risky Bet On Simufilam Cassava Sciences' Simufilam For Alzheimer's Disease: Not As Good As Adverti...
2023-08-23 13:00:00 ET Growth stocks have hit a rough patch lately. The Nasdaq Composite , a benchmark for many growth-oriented companies, has declined by about 5% since the beginning of August, and many individual growth stocks have suffered even bigger losses. However, this recent wea...
2023-08-22 10:00:00 ET The healthcare sector is a hotbed of innovation, and those companies that genuinely break new ground are often handsomely rewarded, along with their shareholders. Investors looking to earn outsized returns over long periods (which describes most investors) would do we...
2023-08-16 11:12:46 ET Summary Sarepta Therapeutics shows strong Q2 revenue growth and progresses in DMD treatment despite net losses. The company's liquidity position is robust with a cash runway of approximately 33 months. Sarepta's advancements in DMD treatment and ongoing ...
2023-08-16 09:31:41 ET Summary There is an ongoing phase 3 study, known as HOPE-3, deploying the use of CAP-1002 for the treatment of patients with Duchenne Muscular Dystrophy; Interim analysis expected Q4 of 2023. A Type-B FDA meeting was held between the company and the FDA; Min...
2023-08-14 08:15:00 ET Summary This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...